← All organizations
Highest phase reached
Phase 2
First clinical trial
Aug 1, 2000Last known activity
Jan 1, 2022
Timeline
1990s
- Jan 1, 1999
Pediatric Brain Tumor Consortium— Founded
Drugs by trial phase (67 distinct, 48 trials)
Phase 2 (30 own, 0 via acquisition)
Phase 1 (29 own, 0 via acquisition)
Other trials (8 own, 0 via acquisition)
Indications
Studied for
- Adamantinoma
- Anemia
- Astrocytoma
- Brain Neoplasms
- Brain Stem Neoplasms
- Central Nervous System Neoplasms
- Choroid Plexus Neoplasms
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Craniopharyngioma
- Ependymoma
- Fanconi Anemia
- Fanconi Syndrome
- Glioblastoma
- Glioma
- Gliosarcoma
- Leukemia
- Leukemia, Myeloid, Acute
- Lymphoma
- Medulloblastoma
- Meningeal Carcinomatosis
- Meningioma
- Meningitis
- Myelodysplastic Syndromes
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Neuroepithelial
- Nervous System Neoplasms
- Neuroblastoma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Neurofibroma
- Neurofibromatoses
- Neurofibromatosis 1
- Oligodendroglioma
- Optic Nerve Glioma
- Pinealoma
- Retinoblastoma
- Rhabdoid Tumor
- Spinal Cord Neoplasms
- Syndrome
Recent trials (50)
- NCT04978727Lead sponsorPhase 1Jan 1, 2022
- NCT04743661Lead sponsorPhase 2Oct 1, 2021
- NCT04903080Lead sponsorPhase 1Sep 3, 2021
- NCT04295759Lead sponsorPhase 1Apr 11, 2020
- NCT04201457Lead sponsorPhase 1/Phase 2Nov 20, 2019
- NCT03904862Lead sponsorPhase 1/Phase 2Apr 30, 2019
- NCT03598244Overall official - principal investigatorPhase 1Nov 7, 2018
- NCT03600909CollaboratorPhase 2May 15, 2018
- NCT03389802Lead sponsorPhase 1Feb 2, 2018
- NCT03387020Overall official - principal investigatorPhase 1Jan 13, 2018
- NCT03387020Lead sponsorPhase 1Jan 13, 2018
- NCT02717455Lead sponsorPhase 1Mar 1, 2016
- NCT02415153Overall official - principal investigatorPhase 1Jul 14, 2015
- NCT02359565Overall official - principal investigatorPhase 1May 22, 2015
- NCT02255461Lead sponsorPhase 1Oct 1, 2014
Details
- Founded
- Memphis, TN, US Jan 1, 1999
- Last known activity
- Jan 1, 2022